SCHEMBL21824294

SCHEMBL21824294

Clc1ccc2cc(-c3csc(-c4ccoc4)n3)oc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 2/20 0.42
▸ F2RL3 Q96RI0 2/20 0.41
▸ MAPT P10636 5/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ RAB9A P51151 4/20 0.39
▸ KDM4E B2RXH2 4/20 0.39
▸ LMNA P02545 3/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ NPC1 O15118 3/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ PIM1 P11309 1/20 0.37
▸ PIM3 Q86V86 1/20 0.37
▸ PIM2 Q9P1W9 1/20 0.37
▸ SREBF2 Q12772 1/20 0.36
▸ CRHBP P24387 1/20 0.36
▸ CRHR2 Q13324 1/20 0.36
▸ ATM Q13315 1/20 0.36
▸ MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21823816 0.83 CYP19A1 (0.61) CYP19A1MAPTALDH1A1MAPK1RAB9A
SCHEMBL21823777 0.82 KDM4E (0.42) CYP19A1F2RL3MAPTALDH1A1RAB9A
SCHEMBL21823785 0.79 CYP19A1 (0.47) CYP19A1F2RL3MAPTALDH1A1MAPK1
SCHEMBL29546326 0.74 CYP19A1 (0.44) CYP19A1F2RL3MAPTALDH1A1MAPK1
SCHEMBL29546491 0.74 RAB9A (0.46) CYP19A1F2RL3MAPTALDH1A1MAPK1
SCHEMBL29546209 0.72 F2RL3 (0.43) CYP19A1F2RL3MAPTALDH1A1MAPK1
SCHEMBL29546434 0.71 SIGMAR1 (0.41) CYP19A1F2RL3MAPTALDH1A1MAPK1
Hydrochloric Acid SCHEMBL29545854 0.70 HTR2C (0.42) CYP19A1F2RL3MAPTALDH1A1MAPK1
SCHEMBL10901632 0.68 SHBG (0.46) CYP19A1F2RL3RAB9A
SCHEMBL21823774 0.67 CYP19A1 (0.69) CYP19A1MAPTALDH1A1MAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3860994-B1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE UNIV BRITISH COLUMBIA (CA) 2024-08-14 — — EP disclosed
US-20220106304-A1 Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2022-04-07 — — US disclosed
EP-3860994-A1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE The University of British Columbia (CA) 2021-08-11 — — EP disclosed
WO-2020069625-A1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2020-04-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220106304-A1 Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use BRDT, CBFB, CREBBP CYP19A1 2345/4885F2RL3 3912/4885MAPT 1816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback